Clinical Trial Update: An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China

View source ↗

Summary

This entry notes the VERI-China observational study assessing vericiguat in real-world patients with chronic heart failure with reduced ejection fraction in Chi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Bayer | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Status: COMPLETED